Division of Basic Medical Research FY2022 List of Projects - Research Program on Hepatitis

Program for Basic and Clinical Research on Hepatitis

First Year	Principal Investigator	Affiliation		Project Title
FY2020	TAKEHARA Tetsuo	Osaka University	Professor	Elucidation of the progression of liver pathology such as liver carcinogenesis after hepatitis C virus elimination and its predictors
FY2020	CHAYAMA Kazuaki	Hiroshima University	Professor	Study of factors associated with health status and prognosis after successful HCV eradication
FY2020	AIZAKI Hideki	National Institute of Infectious Disease	Chief	Study on pathology and course of liver carcinogenesis after sustained virologic response in hepatitis C
FY2020	KUROSAKI Masayuki	Musashino Red Cross Hospital	Vice President	Study on the effect of resistance associated substitutions on clinical features of hepatitis C virus infection
FY2020	TAJIRI Hitoshi	Kindai University Nara Hospital	Researcher	Studies on evaluation of progression of viral hepatitis during childhood and on development of treatment strategy
FY2020	YATSUHASHI Hiroshi	National Hospital Organization Nagasaki Medical Center	President	Study of contributing to improvement of QOL and improvement of prognosis in patients with liver cirrhosis
FY2020	TERAI Shuji	Niigata University	Professor	Translational research aiming for development of next generation exosome therapy for cirrhosis
FY2020	OSAFUNE Kenji	Kyoto University	Professor	Development of cell therapy against liver cirrhosis using human iPS cells and nonhuman primate liver disease models
FY2020	SAKAMOTO Naoya	Hokkaido University	Professor	Screening of prognostic biomarker by comprehensive serum and liver tissue glycomics
FY2020	HONDA Masao	Kanazawa University	Professor	Revealing the association of impaired barrier function of liver sinusoidal endothelial cells and the onset of lifestyle disease related non-B, non-C hepatitis and hepatocellular carcinoma
FY2020	KODAMA Takahiro	Osaka university	Assistant professor	Study of molecular mechanisms of NASH and non-B non-C liver cancer and exploration of their therapeutic targets
FY2020	KANDA Tatsuo	Nihon University School of Medicine	Associate Professor	Research and development of infection prevention, pathological mechanism, diagnosis and treatment for hepatitis A and E viruses
FY2020	UENO Hideki	Kyoto University	Professor	Promoting HBs seroconversion in chronic HBV infection
FY2020	NAKAMOTO Yasunari	University of Fukui	Professor	Development of Novel Targeted Immunotherapy for Chronic Hepatitis B to Regulate both Virus and Carcinogenesis
FY2020	NISHIDA Nao	National Center for Global Health and Medicine	Senior Researcher	Predictive Model to Prevent Development of Liver Disease Based on the Polygenic Risk Score (PRS)
FY2020	MIYOSHI Eiji	Osaka University Graduate School of Medicine	Professor	Study of novel hepatocarcinogenesis mechanism using glycotechnology and its application
FY2020	MURAI Kazuhisa	Kanazawa University	Assistant Professor	Establishment of the research infrastructure for liver cancer microenvironment and exploratory research of a novel cancer immunotherapeutic target
FY2020	ABE Yuichi	Aichi Cancer Center Research Institute	Senior Scientist	Screening of novel diagnostic markers and therapeutic targets for NASH-derived hepatocellular carcinoma by ultra-sensitive multi-omics
FY2021	HIASA Yoichi	Ehime University	Professor	Development of immune therapy to achieve drug-free for the patient with chronic hepatitis B
FY2021	SUZUKI Fumitaka	Toranomon Hospital	Director	The analyses of factors associated with drug free status and try to establish the therapies for setting out to drug free status and HBsAg
FY2021	MIZOKAMI Masashi	National Center for Global Health and Medicine	Project Leader	Development of cost-effective prophylaxis and treatment for hepatitis B virus (HBV) reactivation
FY2021	SUZUKI Tetsuro	Hamamatsu University School of Medicine	Professor	Development of a novel class of anti-HCV agents targeting the viral NS2
FY2021	SAKAI Katsuya	Kanazawa University	Associate Professor	A versatile hepatitis treatment based on recovery from liver dysfunctions and fibrosis achieved by an engineered
FY2021	MIZUGUCHI Hiroyuki	Osaka University	Professor	Development of hepatic tissue derived organoids for the novel treatment of cirrhosis and liver failure
FY2021	KANEYAMA Shuri	Showa University School of Medicine	Associate Professor	Development of the antisense nucleic acid aiming to treat liver fibrosis via extracellular matrix remodeling
FY2021	KOIKE Kazuhiko	The University of Tokyo	Professor Emeritus	Study of pathogenesis of metabolism-associated liver cancer on the background of steatohepatitis
FY2021	KANTO Tatsuya	National Center for Global Health and Medicine	Director General	Development of medicine for NASH patients with liver cancer based on inflammaging lipid-genomics research 2.0
FY2021	OTSUKA Motoyuki	The University of Tokyo	Assistant Professor	Elucidation of the mechanisms of chronic inflammation-induced hepatocarcinogenesis and development of novel
FY2021	NAKATSURA Tetsuya	National Cancer Center	Chief	Development of technology to suppress the onset and recurrence of liver cancer with circulating tumor cells and personalized immunotherapy
FY2021	YOSHIO Sachiyo	National Center for Global Health and Medicine	Chief	Development of novel therapy for the patients with chronic liver disease based on comprehensive understanding of muscle-liver-metabolism axis and immune system
FY2021	YAMASHITA Taro	Kanazawa University	Associate Professor	Development of a novel synthetic ligand optimized for the activation of hepatocyte nuclear factor 4α, a master regulator of liver metabolism, regeneration, and carcinogenesis, to develop an innovative treatment strategy on liver cancer
FY2021	NAKAMOTO Nobuhiro	Keio University	Associate Professor	Study to elucidate the mechanism of liver fibrosis and resolution via inter-organ network
FY2021	YOSHIJI Hitoshi	Nara Medical University	Professor	Development research of novel pathophysiology and therapy for hepatorenal syndrome in cirrhosis -Thrombotic microangiopathy and recombinant ADAMTS13 therapy-
FY2021	SHIOZAWA Yusuke	Nippon Medical School	Assistant Professor	Specific excision of hepatitis B virus covalently closed circular DNA using Cas9 nickase
FY2021	MATSUMOTO Tomonori	Osaka University	Assistant Professor	Exploration of novel treatment strategies for drug resistance and emergence of liver cancers targeting ploidy alterations and senescence escape
FY2021	Xian Yang QIN	RIKEN	Research Scientist	Molecular pathology and drug discovery of liver cancer by tracing dynamic changes of cancer stem cell marker expression
FY2022	MIZUKOSHI Eishiro	Kanazawa University	Associate Professor	Study to prevent liver carcinogenesis after treatment for chronic hepatitis C
FY2022	TANAKA Shinji	Tokyo Medical and Dental University	Professor	Subtype-specific prevention and treatment for occurrence and recurrence of post-SVR hepatocellular carcinoma
FY2022	TANAKA Yasuhito	Kumamoto University	Professor	Elucidation of disease progression including liver carcinogenesis after hepatitis C virus eradication and establishment of preventive method
FY2022	ENOMOTO Nobuyuki	University of Yamanashi	Director	Study on the mechanism of hepatocellular carcinoma development and pathological changes after hepatitis C virus elimination using next generation sequencing technology
FY2022	INAGAKI Yutaka	Tokai University	Professor	Development of novel anti fibrotic therapy based on deactivation of collagen producing cells and original in silico drug design
FY2022	ASAHINA Yasuhiro	Tokyo Medical and Dental University	Professor	Elucidation of mechanisms for liver fibrogenesis and hepatocarcinogenesis using innovative organoid technology and creation of breakthrough anti fibrogenic/carcinogenic treatments
FY2022	KAWADA Norifumi	Osaka City University	Professor	Molecular understanding and therapy development of liver cirrhosis based on bioinformatics analysis of genes associated with hepatic microvascular cell-derived secretome
FY2022	OHDAN Hideki	Hiroshima University	Professor	Research and development of novel hepatitis and hepatocellular carcinoma treatment by immunotherapy using differentiation-regulated NK cells
FY2022	SUZUKI Ryosuke	National Institute of Infectious Diseases	Chief	Basic research to control the propagation and pathogenicity of hepatitis viruses
FY2022	OKAMOTO Toru	Osaka University	Professor	Elucidating pathogenesis of hepatitis viruses for drug discovery
FY2022	TOKUNAGA Katsushi	National Center for Global Health and Medicine	Director	Clinical genome analysis for personalized management of hepatitis B and practical usage of data storage (KANEN-DS)
FY2022	MURATA Kazumoto	Jichi Medical University	Professor	Study of therapeutic strategies and drug discovery for HBsAg reduction in HBV infection, based on immunomodulatory effects of nucleotide analogs
FY2022	TAKEHARA Tetsuo	Osaka University	Professor	Study of elucidating the impact of interferon free treatment on the outcomes, including prognosis, in patients with cirrhosis C
FY2022	KAKAZU Eiji	National Center for Global Health and Medicine	Chief	Study of mitochondria and communication among organ systems in MAFLD
FY2022	NAKAGAWA Hayato	Mie University	Professor	AFP revisited: Development of new therapeutic strategies to promote liver regeneration and prevent carcinogenesis
FY2022	SUZUKI Atsushi	Kyushu University	Professor	The study for developing a method to treat the hepatic cirrhosis using induced hepatic progenitor cells and their secretory component
FY2022	WADA Haruka	Hokkaido University	Associate Professor	Research and development of macrophage therapy for liver cirrhosis aiming an investigator-initiated clinical trial
FY2022	MIYOSHI Masato	Tokyo Medical and Dental University	Project Assistant Professor	Analysis of molecular mechanisms underlying the initial phase of activation of hepatic stellate cells using an original culture method
FY2022	ARIMA Yuichiro	Kumamoto University	Associate Professor	Development of non-alcoholic fatty liver disease treatment method through ketone body metabolism
FY2021	WAKAE Kousho	National Institute of Infectious Diseases	Chief Investigator	Development of a novel relapse marker of hepatocellular carcinoma, based on the amount of human-HBV chimeric DNA

Program on the Innovative Development and the Application of New Drugs for Hepatitis B

First Year	Principal Investigator	Affiliation		Project Title
FY2022	SAKAMOTO Naoya	Hokkaido University	Professor	High-throughput screening of antiviral seed compounds by using HBV cell culture and antiviral response reporter models
FY2022	ITO Kiyoaki	Aichi Medical University	Professor	Development of novel antiviral agents that enable HBV elimination by inhibiting infection of uninfected hepatocytes
FY2022	KATO Takanobu	National Institute of Infectious Diseases	Chief	Study of viral and host factors for the production and maintenance of hepatitis B virus cccDNA
FY2022	WATASHI Koichi	National Institute of Infectious Diseases	Director, Division of Drug Development	Regulation of hepatitis B virus infection by the receptor cofactor and its application to drug development
FY2022	UEDA Keiji	Osaka University Graduate School of Medicine	Professor	Study of host-virus interaction to develop anti-HBV strategy
FY2022	MORIISHI Kohji	Graduate Faculty of Interdisciplinary Research, University of Yamanashi	Professor	Study contributing to the elucidation of the mechanism of genomic activation and replication of hepatitis B virus and the identification of antivirals and host targets
FY2022	SHOJI Ikuo	Kobe University Graduate School of Medicine	Professor	Study of hepatitis B virus propagation and drug discovery research using the reporter HBV system
FY2022	NISHINA Hiroshi	Tokyo Medical and Dental University	Professor	Study of host elimination mechanism of HBV-infected hepatocytes and identification of drug target
FY2022	MIZUKOSHI Eishiro	Kanazawa University	Associate Professor	Study of elucidation of host defense mechanisms against hepatitis B virus and development of immunotherapy
FY2022	FUJITA Takashi	Kyoto University	Visiting Professor	Studies on replication mechanism of HBV and development of novel therapy for HBV infection: novel HBV infection mouse model and screening for cccDNA inhibitors
FY2022	AIZAKI Hideki	National Institute of Infectious Disease	Chief	Elucidation of pathology and development of new treatment methods using hepatitis B virus persistent infection model
FY2022	TAKEHARA Tetsuo	Osaka University	Visiting Senior Researcher	Elucidation of the pathogenesis and development of new treatment using persistent hepatitis B virus infection models
FY2022	CHAYAMA Kazuaki	Hiroshima University	Professor	Development of curative therapy of chronic hepatitis B virus infection using persistent hepatitis B mouse model
FY2022	HONDA Masao	Kanazawa University	Professor	Study of the optimization of new therapies for the removal of HBV and the establishment of theoretical backgrounds
FY2022	MIZOKAMI Masashi	National Center for Global Health and Medicine	Project Leader	Comprehensive research towards the practical application of genome-editing therapy to eliminate the hepatitis B virus
FY2022	KANTO Tatsuya	National Center for Global Health and Medicine	Director General	Development of therapy against chronic hepatitis B with an orallyavailable TLR-7 agonist, SA-5, and establishment of the system for an investigator-initiated FIH study
FY2022	MURAMATSU Masamichi	National Institute of Infectious Diseases	Director	Research and development of anti-HBV therapy and diagnostic drugs
FY2022	TANAKA Yasuhito	Kumamoto University	Professor	Development of new hepatitis B therapeutic agents for clinical application
FY2022	ISOGAWA Masanori	National Institute of Infectious Diseases	Chief	Study for developing novel immunotherapies to achieve functional cure of chronic hepatitis B
FY2022	SUGIYAMA Masaya	National Center for Global Health and Medicine	Vice Project Leader	Elucidation of hepatitis B virus (HBV) POL function and development of new drugs on the basis of technology for full-length HBV-POL expression
FY2022	SAWASAKI Tatsuya	Ehime University	Professor	Study of development of AI-designed Hepatitis B virus polymerase and its inhibitors
FY2022	FUJIMOTO Akihiro	The University of Tokyo	Professor	Comprehensive analysis of full-length transcripts in hepatitis and liver cancer tissues
FY2022	FUKUHARA Takasuke	University of Hokkaido	Professor	Development of genome-editing drugs of adenovirus vector expressing eight multiplex guide RNAs using models of HBV replication in humanized mice and of HBV carcinomas
FY2022	TAKETOMI Akinobu	Hokkaido University	Professor	Study of the clinical significance of previous infection with HBV in HCC and the molecular mechanism of hepatocarcinogenesis in HBc antibody positive patients

Last updated 11/08/22